How an AstraZeneca exec is leading the charge in the next immuno-oncology era

Now, as the head of immuno-oncology and the gastrointestinal tumors franchise at pharma giant AstraZeneca, Goel is leading revolutionary progress in the field. This summer, the company announced results of a long-term study of the checkpoint inhibitors Imfinzi and Imjudo in patients with advanced liver cancer — 25% of whom were alive after four years receiving the drug combo, an unprecedented result for a disease that has historically seen only 7% of patients surviving five years.